Theranostic biomarkers in hypertrophic cardiomyopathy insights in a long road ahead (original) (raw)

Theranostic approaches in hypertrophic cardiomyopathy 1725 © 1996-2017 cardiac disease (3). Few cardiac diseases are as heterogeneous as HCM. In fact, its timing of onset, phenotype and clinical course show extreme individual variability. Even within members of the same family, the reasons for such diversity are not completely understood and potentially range from genetic/ epigenetic to environmental factors. dysfunction (CMD), positron emission tomography (PET), single-photon emission computed tomography (SPECT), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), metalloproteinases (MMPs), renin-angiotensin-aldosterone system (RAAS), microRNAs (miRNAs), myosin heavy chain (MHC), beta-MHC (MYH7), alpha-MHC (MYH6)

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact